Beyondspring (NASDAQ: BYSI) and NewLink Genetics (NASDAQ:NLNK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Institutional and Insider Ownership
1.2% of Beyondspring shares are owned by institutional investors. Comparatively, 65.1% of NewLink Genetics shares are owned by institutional investors. 13.7% of NewLink Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Beyondspring and NewLink Genetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NewLink Genetics||$28.71 million||10.67||-$71.95 million||($2.35)||-3.51|
Beyondspring has higher earnings, but lower revenue than NewLink Genetics.
This is a summary of current ratings and recommmendations for Beyondspring and NewLink Genetics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyondspring currently has a consensus price target of $54.50, suggesting a potential upside of 91.36%. NewLink Genetics has a consensus price target of $23.67, suggesting a potential upside of 187.22%. Given NewLink Genetics’ higher possible upside, analysts clearly believe NewLink Genetics is more favorable than Beyondspring.
This table compares Beyondspring and NewLink Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NewLink Genetics beats Beyondspring on 5 of the 9 factors compared between the two stocks.
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.